NotableRecruitment openedShow 6 more changesShow less
Trial sites expanded: 2 → 8 locations
Primary completion date: Jun 12, 2029 to Jun 1, 2029
Study completion date: Sep 4, 2029 to Aug 24, 2029
Start date changed from estimate of Aug 24, 2026 to Aug 20, 2026
Eligibility criteria expanded, about 11 words
Secondary endpoints: details revised at 8 of 36 entries
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected.
The study is seeking participants who:
* Have a history of severe asthma for at least 12 months
* Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic.
The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.